An Introduction to Diabetes
Diabetes is an enormous health burden worldwide, and the current epidemic of type 2 diabetes is of paramount concern. The most important recent advances in the management of type 1 diabetes have been immunotherapies, designed to delay disease onset and the development of fully automated artificial pancreas systems that integrate blood glucose monitoring and insulin delivery. In type 2 diabetes, the widespread use of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors have facilitated optimal glycaemic control without increased risk of hypoglycaemia and weight gain. Emerging data from cardiovascular outcome trials have shown that these agents can reduce the risk of cardiovascular disease in high-risk individuals.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
John Doupis: ADA 83rd Scientific Sessions, 2023: Type 2 diabetes highlights
Dr. John Doupis (Director, Iatriko Paleou Falirou Medical Center, Diabetes Division, Athens, Greece; Editor-in-Chief, touchREVIEWS in Endocrinology) provides his top three highlights from the ADA 83rd Scientific Sessions, 2023 in the field of type 2 diabetes. Disclosures: John Doupis has received consultant fees from Elli Lilly, Novo Nordisk, Abbott, Astra Zeneca and Boehringer Ingelheim. He […]
Alarming Surge in Early-onset Type 2 Diabetes: A Global Catastrophe on the Horizon
touchREVIEWS in Endocrinology. 2023;19(2):1–2:Online ahead of journal publication
Diabetes mellitus (DM) is a group of metabolic disorders marked by elevated blood glucose. It has many subtypes, including type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), gestational diabetes and neonatal diabetes; of these, T1DM and T2DM are the most common. Compared with T1DM, which is characterized by a chronic lack of insulin […]
Chantal Mathieu: ADA 83rd Scientific Sessions, 2023: Research highlights
Prof. Chantal Mathieu (Katholieke Universiteit Leuven, Belgium) provides her highlights from the ADA 83rd Scientific Sessions, 2023 including Teplizumab, an anti-CD3 monoclonal antibody, which was the first disease modifying therapy that delays the progression from stage 2 to stage 3 type 1 diabetes and was FDA approved in November 2022; Orforglipron, an oral, non-peptide glucagon-like […]
Steven Nissen, ADA 2023: Bempedoic acid for cardiovascular disease risk: The CLEAR Outcomes trial
The CLEAR Outcomes trial was a double-blind, randomized, placebo-controlled trial involving patients who were “statin-intolerant” and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. Dr. Steven Nissen (Heart, Vascular and Thoracic Institute, Cleveland Clinic Center for Clinical Research, Cleveland, OH, […]
What is Glycaemic Variability and which Pharmacological Treatment Options are Effective? A Narrative Review
touchREVIEWS in Endocrinology. 2023;19(2):Online ahead of journal publication
The incidence of diabetes has increased in recent years, and advances in technology have allowed for multiple ways to predict the outcomes of patients with diabetes, and have improved quality of life and lowered morbidity and mortality.1 For decades, glycated haemoglobin (HbA1c) has been used as a marker of long-term glycaemic control, and its usefulness as […]
Sean Wharton, ADA 2023: Oral nonpeptide GLP-1 receptor agonist orforglipron for obesity
Orforglipron (LY3502970) is a novel oral non-peptide GLP-1 receptor agonist being developed for patients with obesity or overweight, particularly those with type-2 diabetes. Dr. Sean Wharton (Adjunct Professor at McMaster University and Medical Director of the Wharton Medical Clinic) discusses the Phase 2 study, including likely clinical impacts, and future directions following these findings. The […]
Akhtar Hussain, International Diabetes Federation (IDF): Presidential update
The International Diabetes Federation (IDF) is the global voice of the diabetes community. They are a non-profit umbrella organisation of more than 240 national diabetes associations in 161 countries and territories, working together to improve and empower the lives of the 540 million people estimated to be living with diabetes and prevent diabetes in those […]
Clinical Profile and Factors Associated with Adverse Outcomes in Coronavirus Disease 2019-associated Mucormycosis: A Single-centre Study
touchREVIEWS in Endocrinology. 2023;19(2):Epub ahead of journal publication DOI: https://doi.org/10.17925/EE.2023.19.2.2
Plan language summary Background The global COVID-19 pandemic resulted in an increased incidence of infection with Black fungus (Mucormycosis). However, the disease characteristics, chances of spread of infection and complications are not well known. Aim of the study We tried to find out the exact reasons behind this rise in the number of cases, whether […]
Foreword: touchREVIEWS in Endocrinology 19.1
Welcome to the latest edition of touchREVIEWS in Endocrinology. In this edition we feature a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We start with a focus on diabetes. An editorial from Bhattacharya and Kalra gives an overview of the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!